Nonalcoholic steatohepatitis pipeline insight report 2021 - researchandmarkets.com
Dublin--(business wire)--the "nonalcoholic steatohepatitis - pipeline insight, 2021" drug pipelines has been added to researchandmarkets.com's offering. this "nonalcoholic steatohepatitis - pipeline insight, 2021," report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in nonalcoholic steatohepatitis pipeline landscape. it covers the pipeline drug profiles, including clinical and nonclinical stage products. it also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. it further highlights the inactive pipeline products in this space. report highlights the companies and academics are working to assess challenges and seek opportunities that could influence nonalcoholic steatohepatitis r&d. the therapies under development are focused on novel approaches to treat/improve nonalcoholic steatohepatitis. nonalcoholic steatohepatitis emerging drugs chapters this segment of the nonalcoholic steatohepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase ii, i, preclinical and discovery. it also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. nonalcoholic steatohepatitis emerging drugs semaglutide: novo nordisk semaglutide is a long-acting glp-1 analog intended as a once-daily treatment for nonalcoholic fatty liver disease (nash). it is currently in the phase iii stage of development for nash and is being developed by novo nordisk. resmetirom: madrigal pharmaceuticals resmetirom (mgl-3196) is a first-in-class, orally-administered, small-molecule, liver-directed thyroid hormone receptor (thr) selective agonist. preclinical, toxicology, phase 1, and phase 2 clinical data suggest resmetirom has an attractive, differentiated profile as a potential treatment for nonalcoholic steatohepatitis (nash), nonalcoholic fatty liver disease (nafld) and associated dyslipidemias. oltipraz: pharmaking oltipraz is currently in the phase iii stage of development for nonalcoholic steatohepatitis (nash). it is being developed by pharmaking and acts as glutathione transferase stimulants, liver x receptor antagonists, nqo1 stimulants, and ribosomal protein s6 kinase modulators. als-l1023: angiolab als l1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from melissa leaf (lemon balm). the angiogenesis inhibitor als-l1023 from lemon-balm leaves attenuates high-fat diet-induced nonalcoholic fatty liver disease through regulating the visceral adipose-tissue function. the drug is currently being investigated in phase ii clinical trials for the treatment of patients with nonalcoholic steatohepatitis. ormd-0801: oramed oramed's oral insulin (ormd-0801) has the potential to create a new paradigm in the treatment of diabetes and nonalcoholic steatohepatitis by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. a phase ii clinical trial is currently being evaluated for ormd-801 in the patients with nonalcoholic steatohepatitis. cb4211: cohbar cb4211 is our novel, refined analog of mots-c, a naturally occurring mitochondrial peptide. mots-c plays a significant role in the regulation of metabolism. cb4211 also inhibits adipocyte lipolysis, a process that is foundational in the development of liver steatosis, through an insulin-dependent mechanism. the drug is being developed and investigated by cohbar in phase i for the treatment of nonalcoholic steatohepatitis. nonalcoholic steatohepatitis: therapeutic assessment this segment of the report provides insights about the different nonalcoholic steatohepatitis drugs segregated based on following parameters that define the scope of the report, such as: major players in nonalcoholic steatohepatitis there are approx. 140+ key companies which are developing the therapies for nonalcoholic steatohepatitis. the companies which have their nonalcoholic steatohepatitis drug candidates in the most advanced stage, i.e. phase iii include, madrigal pharmaceuticals. nonalcoholic steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the route of administration. products have been categorized under various roas such as oral parenteral intravenous subcutaneous topical molecule type products have been categorized under various molecule types such as monoclonal antibody peptides hepatoprotectant small molecule cell therapy antisense oligonucleotides recombinant proteins small interfering rna product type the drugs have been categorized under various product types like mono, combination and mono/combination. nonalcoholic steatohepatitis: pipeline development activities the report provides insights into different therapeutic candidates in phase ii, i, preclinical and discovery stage. it also analyses nonalcoholic steatohepatitis therapeutic drugs key players involved in developing key drugs. pipeline development activities the report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging nonalcoholic steatohepatitis drugs. nonalcoholic steatohepatitis report insights nonalcoholic steatohepatitis pipeline analysis therapeutic assessment unmet needs impact of drugs nonalcoholic steatohepatitis report assessment pipeline product profiles therapeutic assessment pipeline assessment inactive drugs assessment unmet needs key players novo nordisk madrigal pharmaceuticals pharmaking cirius therapeutics inventiva pharma galmed pharmaceuticals abbvie galectin therapeutics viking therapeutics sagimet biosciences novartis hepion pharmaceuticals celgene boston pharmaceuticals bristol-myers squibb ngm biopharmaceuticals boehringer ingelheim axcella health corcept therapeutics taiwanj pharmaceuticals angiolab oramed can-fite biopharma mitsubishi tanabe pharma medicinova merck sharp & dohme metacrine medimmune lipocine chemomab therapeutics afimmune northsea therapeutics rivus pharmaceuticals hightide biopharma hanmi pharmaceutical enyo pharma histogen akero therapeutics enanta pharmaceuticals gilead sciences ionis pharmaceuticals eli lilly and company terns pharmaceuticals sinew pharma poxel cytodyn future medicine 89bio ltd. hk inno.n arrowhead pharmaceuticals promethera biosciences enanta pharmaceuticals key products semaglutide resmetirom oltipraz msdc-0602k lanifibranor aramchol cenicriviroc belapectin vk2809 tvb-2640 tropifexor (ljn452) crv431 cc-90001 bos-580 bms-986263 aldafermin bi 456906 axa1125 miricorilant jkb-122 als-l1023 ormd-0801 namodenoson mn-001 mt-3995 mk-3655 met642 medi 0382 lys006 lpcn 1144 cm101 epeleuton icosabutate hu6 htd1801 hm15211 epy001a emricasan efruxifermin (efx) edp-305 firsocostat ion224 tirzepatide tern-101 snp-610 pxl770 leronlimab fm101 bio89-100 in-a010 aro-hsd hepastem edp-297 for more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yjo734
